Azole Derivatives: Cutting‐Edge Agents in Cancer Therapy
- 12 November 2024
- journal article
- review article
- Published by Wiley in ChemistrySelect
- Vol. 9 (43)
Abstract
Monocyclic 5‐membered heterocycles including imidazoles, thiazoles, oxazoles, and their related compounds have gained significant attention in medicinal chemistry because of their potent anticancerous activity. These small heterocyclic molecules possess versatile properties, including biological activity, absorption, distribution, metabolism, excretion, and chemical diversity that give them immense potential as anticancer agents. It is also a fact that inherent characteristic of azoles to combine with many biological molecules through hydrogen bond, stacking, and hydrophobic interaction makes them effective against almost all cancer types. In the present paper the author discusses the way which is connected with chemical structure of monocyclic azoles and their anticancer activity namely the ability of these compounds to intercalate with DNA, to inhibit some enzymes and to interfere cellular signaling pathways. Interestingly, several azole derivatives have been seen to be effective in preclinical efficacy studies as well as in clinical trials and are considered to be potent in overcoming the problem of resistance and side effects of the common anticancer agents. As the synthetic chemistry progresses, the structural system of the azoles has diversified and development in the pharmacology has become more specific. This has helped in enhancing the formation of new molecules in the azole class with improved selectivity and efficacy. Furthermore, the comprehensive review explains how computational chemistry and structure‐activity relationship (SAR) approaches are applied to the design of future‐generation azole compounds. In light of these facts, this article is designed to give a broad overview of the current state of monocyclic azole‐based anticancer agents in an attempt to further assert its therapeutic promise and spur further attempts at infusing the said agents into the cancer therapeutics fray. The discoveries made in this study may allow the development the radical different therapeutic approaches, which could lead to improved and targeted treatment of cancer.Keywords
This publication has 106 references indexed in Scilit:
- Synthesis and Molecular Docking of some new Thiazolidinone and Thiadiazole Derivatives as Anticancer AgentsChemistry & Biodiversity, 2024
- Synthesis of Indole‐Linked Thiadiazoles and their Anticancer Action against Triple‐Negative Breast CancerChemistry & Biodiversity, 2024
- Synthesis, characterization of novel N‐(4‐cyano‐1,3‐oxazol‐5‐yl)sulfonamide derivatives and in vitro screening their activity against NCI‐60 cancer cell linesChemMedChem, 2024
- Synthesis, Characterization and in vitro Anticancer Evaluation of 5‐Sulfinyl(sulfonyl)‐4‐arylsulfonyl‐Substituted 1,3‐OxazolesChemMedChem, 2023
- Anticancer Activities of Tetrasubstituted Imidazole‐Pyrimidine‐Sulfonamide Hybrids as Inhibitors of EGFR MutantsChemMedChem, 2023
- Synthesis of New Pyrimidine‐Triazole Derivatives and Investigation of Their Anticancer ActivitiesChemistry & Biodiversity, 2022
- 1,2,3‐Triazole hybrids as anticancer agents: A reviewArchiv der Pharmazie, 2021
- Synthesis, Characterization, and Biological Study of 3‐Trifluoromethylpyrazole Tethered Chalcone‐Pyrrole and Pyrazoline‐Pyrrole DerivativesChemistry & Biodiversity, 2021
- Synthesis, biological evaluation, and in silico study of pyrazoline‐conjugated 2,4‐dimethyl‐1H‐pyrrole‐3‐carboxylic acid derivativesArchiv der Pharmazie, 2020
- One‐pot synthesis and biological evaluation of novel 4‐[3‐fluoro‐4‐(morpholin‐4‐yl)]phenyl‐1H‐1,2,3‐triazole derivatives as potent antibacterial and anticancer agentsJournal of Heterocyclic Chemistry, 2020